James O Armitage MD and Richard M Stone MD on Clinical Trial Results for AML MDS and CMML Treatment

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 625, “Sustained Remission With the Combination Biologic Doublet of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma: A Multicenter Phase II Study Report,” presented by Jia Ruan, MD, PhD.

Hematologic Malignancies

Ayalew Tefferi, MD

James O. Armitage, MD, FACP, FRCP, and Bertrand Coiffier, MD, PhD, on Managing Lymphoma: The French Perspective

James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Bertrand Coiffier, MD, PhD, of the Centre Hospitalier Lyon-Sud discuss three French studies on rituximab maintenance vs wait and watch after R-DHAP in mantle cell lymphoma; R-CHOP with or without radiotherapy in diffuse large B-cell lymphoma; and romidepsin and CHOP in peripheral T-cell lymphoma.

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment

Related Videos

Laurie Sehn, MD, on Lenalidomide Plus Rituximab in Previously Untreated Mantle Cell Lymphoma

Ayalew Tefferi, MD, on Imetelstat as Therapy for Myelofibrosis

Richard M. Stone, MD, on the SWOG S1117 Study

Linda J. Burns, MD, on a Phase II Study of ACE-536 in Beta-Thalassemia

James O. Armitage, MD, FACP, FRCP, and Bertrand Coiffier, MD, PhD, on Managing Lymphoma: The French Perspective

Alectinib Approved as Adjuvant Treatment for ALK-Positive Non–Small Cell Lung Cancer

Professional Societies Introduce New Evidence-Based Guidelines on Testing Immunotherapy Biomarkers in NSCLC

Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations

Novel MDM2 Inhibitor Shows Activity in Salivary Gland Cancers

Novel SPECT/CT Imaging Technique Under Study in Prostate Cancer